FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Rombotis Spiro George				<u>Cy</u>	2. Issuer Name and Ticker or Trading Symbol Cyclacel Pharmaceuticals, Inc. [CYCC]								(Che	ck all applic	10% (son(s) to Issu 10% Ow Other (s	ner		
(Last)	(F	irst)	(Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/30/2023)	below)			below)	pecity
C/O CYCLACEL PHARMACEUTICALS, INC.					55,55,2525										President and CEO					
200 CONNELL DRIVE, SUITE 1500				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street))							
BERKEI HEIGHT	ERKELEY NI 07922															Form filed by More than One Reporting Person				
	·					Rule 10b5-1(c) Transaction Indication														
(City) (State) (Zip)								ion was n	nada nura	and appropriate a contract instruction or written plan that is intended to										
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												10		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Da		Date	Code (Ins		on					es Forn ally (D) o Following (I) (Ir		n: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Cod	le	v	Amount	t (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Yea	ate,	Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			le and	7. Title and Amoun of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code V				Date Exerci			oiration e	or Nun		nount imber Shares		Transaction(s) (Instr. 4)			
Stock Option (right to buy)	\$0.5891	06/30/2023			A		110,000		06/30/	2024	06/3	30/2033	Common Stock	ⁿ 11	0,000	\$0 ⁽¹⁾	110,00)0	D	

Explanation of Responses:

1. The reporting person received an award of 110,000 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options

shall vest in full earlier in connection with such achievement.

/s/ Spiro Rombotis

07/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).